Home
About
Our Story
Starlights's Focus
Leadership
Pipeline
STAR-001
Posters
Publications
Clinial Trial
Ongoing Trials
Upcoming Trials
Investigator Led Trials
Media
Press Releases
Videos
Contact
Media
News
Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS
Starlight Therapeutics— a Lantern Pharma (Nasdaq: LTRN)...
Button Text
Lantern Pharma Announces Formation of Starlight Therapeutics
Starlight Therapeutics— a Lantern Pharma (Nasdaq: LTRN)...
Button Text
Lantern Pharma Achieves Key Milestone Towards Development of Molecular
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical...
Button Text
Press Releases
Jul 10, 2024
Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184
Button Text
Jan 17, 2024
Lantern Pharma Announces Formation of Starlight Therapeutics to Advance Transformative Therapies for CNS (Central Nervous System) and Brain Cancers
Mar 06, 2023
Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer
Videos
Aug 1, 2024
Starlight Therapeutics - Born from AI, Lighting the Way in CNS Cancer Treatment
June 26, 2024
STAR-001 in Multiple Brain and CNS Cancers
May 26, 2022
Brain Tumor Awareness Month GBM KOL Webinar
Aug 1, 2024
Starlight Therapeutics - Born from AI, Lighting the Way in CNS Cancer Treatment
June 26, 2024
STAR-001 in Multiple Brain and CNS Cancers
May 26, 2022
Brain Tumor Awareness Month GBM KOL Webinar
.png)
.png)
.png)
.png)
.jpg)
